Back

CYP2C19-dependent clopidogrel resistance is a possible cause for coronary stent and peripheral bypass occlusion

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Antiplatelet and anticoagulant drugs Antiplatelet Drugs ESC Premium Access ESC Congress 2018

About the speaker

Photo
Associate Professor Milka Klinceva

Zan Mitrev Clinic, Skopje (North Macedonia)

5 More presentations in this session

Presentation thumbnail
Aspirin resistance in patients with stable coronary heart disease
Doctor T. Petroni (Montauban, FR)
Abstract
Presentation thumbnail
Fourier-spectroscopy capacity in assessment of resistance to acetylsalicylic acid in patients with stable angina pectoris
Mrs A. Kosinova (Elvas, PT)
Abstract Slides
Presentation thumbnail
Residual risk following myocardial infarction despite intensive medical management
Professor R. Rosenson (New York City, US)
Abstract Slides
Presentation thumbnail
Role of rivaroxaban in left ventricular thrombi
Doctor A. Almaghraby (Ras Al Khaimah, AE)
Abstract Slides
Presentation thumbnail
Time to event analysis in patients managed on rivaroxaban while taking concurrent interacting medications (CIM)
Doctor J. Michel (Austin, US)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 1 - Antiplatelet and anticoagulant drugs

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Parenteral antiplatelet agents: when should they be used?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources